124 related articles for article (PubMed ID: 8220147)
61. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.
Yagita M; Ieki Y; Onishi R; Huang CL; Adachi M; Horiike S; Konaka Y; Taki T; Miyake M
Int J Oncol; 1998 Jul; 13(1):91-6. PubMed ID: 9625808
[TBL] [Abstract][Full Text] [Related]
62. A new chromosomal three-way rearrangement involving MLL masked by a t(9;19)(p11;p13) in an infant with acute myeloid leukemia.
de Jesus Marques-Salles T; Liehr T; Mkrtchyan H; Raimondi SC; Tavares de Souza M; de Figueiredo AF; Rouxinol S; Jordy Macedo FC; Abdelhay E; Santos N; Macedo Silva ML
Cancer Genet Cytogenet; 2009 Feb; 189(1):59-62. PubMed ID: 19167614
[TBL] [Abstract][Full Text] [Related]
63. Therapy-related acute myeloblastic leukaemia (M1) with a 9;11 translocation.
Hallett J; Aronson I; Jacobs P
Br J Haematol; 1995 Jun; 90(2):489-90. PubMed ID: 7794780
[No Abstract] [Full Text] [Related]
64. Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Inaba T; Fujita N; Moriguchi T; Yamamoto K; Seto M; Ueda R
Int J Hematol; 1994 Aug; 60(2):145-9. PubMed ID: 7948964
[TBL] [Abstract][Full Text] [Related]
65. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Bagal B; Kumar R; Gaur T; Talreja V; Bonda A; Patkar N; Shetty D; Kowtal P; Subramanian PG; Gupta S; Sarin R; Hasan SK
Med Oncol; 2020 Apr; 37(5):48. PubMed ID: 32277283
[TBL] [Abstract][Full Text] [Related]
66. Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases.
Gillis S; Sofer O; Zelig O; Dann EJ; Lotan H; Ben Yehuda D; Isacson R; Rachmilewitz EA; Ben-Bassat I; Polliack A
Ann Oncol; 1995 Oct; 6(8):777-9. PubMed ID: 8589014
[TBL] [Abstract][Full Text] [Related]
67. Recurrent Translocations in Topoisomerase Inhibitor-Related Leukemia Are Determined by the Features of DNA Breaks Rather Than by the Proximity of the Translocating Genes.
Lomov NA; Viushkov VS; Ulianov SV; Gavrilov AA; Alexeyevsky DA; Artemov AV; Razin SV; Rubtsov MA
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077220
[TBL] [Abstract][Full Text] [Related]
68. Topoisomerase II and leukemia.
Pendleton M; Lindsey RH; Felix CA; Grimwade D; Osheroff N
Ann N Y Acad Sci; 2014 Mar; 1310(1):98-110. PubMed ID: 24495080
[TBL] [Abstract][Full Text] [Related]
69. Influence of DNA damage and repair upon the risk of treatment related leukemia.
Guillem V; Tormo M
Leuk Lymphoma; 2008 Feb; 49(2):204-17. PubMed ID: 18231906
[TBL] [Abstract][Full Text] [Related]
70. Therapy related leukemias: susceptibility, prevention and treatment.
Leone G; Voso MT; Sica S; Morosetti R; Pagano L
Leuk Lymphoma; 2001 Apr; 41(3-4):255-76. PubMed ID: 11378539
[TBL] [Abstract][Full Text] [Related]
71. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor.
Ezoe S
Int J Environ Res Public Health; 2012 Jul; 9(7):2444-53. PubMed ID: 22851953
[TBL] [Abstract][Full Text] [Related]
72. Molecular biology of therapy-related leukaemias.
Joannides M; Grimwade D
Clin Transl Oncol; 2010 Jan; 12(1):8-14. PubMed ID: 20080465
[TBL] [Abstract][Full Text] [Related]
73. Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.
Shim H; Chi HS; Jang S; Seo EJ; Park CJ; Lee JH; Lee JH; Lee KH
Korean J Hematol; 2010 Sep; 45(3):177-82. PubMed ID: 21120206
[TBL] [Abstract][Full Text] [Related]
74. Toxicity of the topoisomerase II inhibitors.
Seiter K
Expert Opin Drug Saf; 2005 Mar; 4(2):219-34. PubMed ID: 15794715
[TBL] [Abstract][Full Text] [Related]
75. Acute promyelocytic leukemia with t(15;17) following inhibition of DNA topoisomerase II.
Pedersen-Bjergaard J
Ann Oncol; 1995 Oct; 6(8):751-3. PubMed ID: 8589010
[No Abstract] [Full Text] [Related]
76. Epipodophyllotoxins and secondary leukaemia.
Kumar L
Lancet; 1993 Oct; 342(8875):819-20. PubMed ID: 8104269
[No Abstract] [Full Text] [Related]
77. The secondary leukemias: challenges and research directions.
Smith MA; McCaffrey RP; Karp JE
J Natl Cancer Inst; 1996 Apr; 88(7):407-18. PubMed ID: 8618232
[TBL] [Abstract][Full Text] [Related]
78. Increase therapy-related leukemia secondary to breast cancer.
Carli PM; Sgro C; Parchin-Geneste N; Isambert N; Mugneret F; Girodon F; Maynadié M
Leukemia; 2000 Jun; 14(6):1014-7. PubMed ID: 10865966
[TBL] [Abstract][Full Text] [Related]
79. Prolonged survival in patients with treatment-related leukemia.
Kingsley EC; Durie BG
Scand J Haematol; 1986 Aug; 37(2):103-5. PubMed ID: 3464086
[TBL] [Abstract][Full Text] [Related]
80. Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Cowell IG; Austin CA
Cell Cycle; 2012 Sep; 11(17):3143-4. PubMed ID: 22894901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
